The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://murrayxzbv140542.tkzblog.com/38820374/glp-3-retatrutide-a-comparative-analysis